Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth

Oncogene
Y-P SherM-C Hung

Abstract

There are currently no effective therapies for cancer patients with advanced ovarian cancer, therefore developing an efficient and safe strategy is urgent. To ensure cancer-specific targeting, efficient delivery, and efficacy, we developed an ovarian cancer-specific construct (Survivin-VISA-hEndoyCD) composed of the cancer specific promoter survivin in a transgene amplification vector (VISA; VP16-GAL4-WPRE integrated systemic amplifier) to express a secreted human endostatin-yeast cytosine deaminase fusion protein (hEndoyCD) for advanced ovarian cancer treatment. hEndoyCD contains an endostatin domain that has tumor-targeting ability for anti-angiogenesis and a cytosine deaminase domain that converts the prodrug 5-fluorocytosine (5-FC) into the chemotherapeutic drug, 5-fluorouracil. Survivin-VISA-hEndoyCD was found to be highly specific, selectively express secreted hEndoyCD from ovarian cancer cells, and induce cancer-cell killing in vitro and in vivo in the presence of 5-FC without affecting normal cells. In addition, Survivin-VISA-hEndoyCD plus 5-FC showed strong synergistic effects in combination with cisplatin in ovarian cancer cell lines. Intraperitoneal (i.p.) treatment with Survivin-VISA-hEndoyCD coupled with liposome a...Continue Reading

References

Oct 1, 1988·American Journal of Clinical Oncology·J A KishM al-Sarraf
Jun 1, 1996·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·S L ParsonsR J Steele
Jul 1, 1997·Nature Biotechnology·N S TempletonG N Pavlakis
Apr 1, 1998·Journal of the National Cancer Institute·J YonedaI J Fidler
Feb 24, 2001·Cancer Metastasis Reviews·B K SimE R Gubish
Dec 6, 2001·Proceedings of the National Academy of Sciences of the United States of America·M IyerS S Gambhir
May 7, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Colin P J GloverJames B Uney
Jan 2, 2003·Nature Reviews. Cancer·Dario C Altieri
Mar 17, 2004·Molecular Cell·Amir AbdollahiPeter E Huber
Mar 22, 2005·Current Medicinal Chemistry. Anti-cancer Agents·Michael GüntherManfred Ogris
Jun 21, 2005·Journal of Cellular and Molecular Medicine·Nadia ZaffaroniMaria Grazia Daidone
Jun 22, 2005·Journal of Pharmaceutical and Biomedical Analysis·Rossella PisanoChristopher A James
Mar 25, 2006·Journal of Cellular Physiology·Fengzhi Li, Xiang Ling
Mar 3, 2009·Hematology/oncology Clinics of North America·Alberto S Pappo, Katherine A Janeway
Apr 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David S MillerCecelia H Boardman
Aug 13, 2009·Molecular Cancer Therapeutics·Xiaoming XieMien-Chie Hung
Jul 9, 2010·CA: a Cancer Journal for Clinicians·Ahmedin JemalElizabeth Ward
Jul 2, 2011·Nature·UNKNOWN Cancer Genome Atlas Research Network

❮ Previous
Next ❯

Citations

Nov 4, 2015·Advanced Drug Delivery Reviews·Pei Yun TeoYi Yan Yang
Jul 4, 2018·International Journal of Molecular Sciences·Ángela ÁyenHouria Boulaiz

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.